These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 38705821)

  • 1. Mitigating treatment failure of pulmonary pre-extensively drug-resistant tuberculosis: The role of new and repurposed drugs.
    Huang YW; Yu MC; Lin CB; Lee JJ; Lin CJ; Chien ST; Lee CH; Chiang CY
    J Microbiol Immunol Infect; 2024 Aug; 57(4):617-628. PubMed ID: 38705821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High fluoroquinolone resistance proportions among multidrug-resistant tuberculosis driven by dominant L2 Mycobacterium tuberculosis clones in the Mumbai Metropolitan Region.
    Dreyer V; Mandal A; Dev P; Merker M; Barilar I; Utpatel C; Nilgiriwala K; Rodrigues C; Crook DW; ; Rasigade JP; Wirth T; Mistry N; Niemann S
    Genome Med; 2022 Aug; 14(1):95. PubMed ID: 35989319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence-based Definition for Extensively Drug-Resistant Tuberculosis.
    Roelens M; Battista Migliori G; Rozanova L; Estill J; Campbell JR; Cegielski JP; Tiberi S; Palmero D; Fox GJ; Guglielmetti L; Sotgiu G; Brust JCM; Bang D; Lienhardt C; Lange C; Menzies D; Keiser O; Raviglione M
    Am J Respir Crit Care Med; 2021 Sep; 204(6):713-722. PubMed ID: 34107231
    [No Abstract]   [Full Text] [Related]  

  • 4. Revised Definitions of Tuberculosis Resistance and Treatment Outcomes, France, 2006-2019.
    Kherabi Y; Fréchet-Jachym M; Rioux C; Yazdanpanah Y; Méchaï F; Pourcher V; Robert J; Guglielmetti L;
    Emerg Infect Dis; 2022 Sep; 28(9):1796-1804. PubMed ID: 35997386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Additional Drug Resistance in Patients with Multidrug-resistant Tuberculosis in Korea: a Multicenter Study from 2010 to 2019.
    Lee T; Lee SJ; Jeon D; Lee HY; Kim HJ; Kang BH; Mok J
    J Korean Med Sci; 2021 Jul; 36(26):e174. PubMed ID: 34227261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes of pulmonary MDR-TB: impacts of fluoroquinolone resistance and linezolid treatment.
    Jeong BH; Jeon K; Park HY; Kwon OJ; Lee KS; Kim HK; Choi YS; Kim J; Huh HJ; Lee NY; Koh WJ
    J Antimicrob Chemother; 2015 Nov; 70(11):3127-33. PubMed ID: 26203184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment outcomes of patients with multidrug-resistant and extensively drug resistant tuberculosis in Hunan Province, China.
    Alene KA; Yi H; Viney K; McBryde ES; Yang K; Bai L; Gray DJ; Clements ACA; Xu Z
    BMC Infect Dis; 2017 Aug; 17(1):573. PubMed ID: 28814276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
    Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
    Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating newly approved drugs in combination regimens for multidrug-resistant tuberculosis with fluoroquinolone resistance (endTB-Q): study protocol for a multi-country randomized controlled trial.
    Patil SB; Tamirat M; Khazhidinov K; Ardizzoni E; Atger M; Austin A; Baudin E; Bekhit M; Bektasov S; Berikova E; Bonnet M; Caboclo R; Chaudhry M; Chavan V; Cloez S; Coit J; Coutisson S; Dakenova Z; De Jong BC; Delifer C; Demaisons S; Do JM; Dos Santos Tozzi D; Ducher V; Ferlazzo G; Gouillou M; Khan U; Kunda M; Lachenal N; LaHood AN; Lecca L; Mazmanian M; McIlleron H; Moreau M; Moschioni M; Nahid P; Osso E; Oyewusi L; Panda S; Pâquet A; Thuong Huu P; Pichon L; Rich ML; Rupasinghe P; Salahuddin N; Sanchez Garavito E; Seung KJ; Velásquez GE; Vallet M; Varaine F; Yuya-Septoh FJ; Mitnick CD; Guglielmetti L
    Trials; 2023 Nov; 24(1):773. PubMed ID: 38037119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Performance of the GenoType MTBDRsl assay for the detection second-line anti-tuberculosis drug resistance.
    Lee YS; Lee BY; Jo KW; Shim TS
    J Infect Chemother; 2017 Dec; 23(12):820-825. PubMed ID: 29066216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidemiology of extensively drug-resistant tuberculosis among patients with multidrug-resistant tuberculosis: A systematic review and meta-analysis.
    Diriba G; Alemu A; Yenew B; Tola HH; Gamtesa DF; Mollalign H; Eshetu K; Moga S; Abdella S; Tollera G; Kebede A; Dangisso MH
    Int J Infect Dis; 2023 Jul; 132():50-63. PubMed ID: 37072053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The diagnostic accuracy of the GenoType(®) MTBDRsl assay for the detection of resistance to second-line anti-tuberculosis drugs.
    Theron G; Peter J; Richardson M; Barnard M; Donegan S; Warren R; Steingart KR; Dheda K
    Cochrane Database Syst Rev; 2014 Oct; (10):CD010705. PubMed ID: 25353401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis.
    Kwon YS; Kim YH; Suh GY; Chung MP; Kim H; Kwon OJ; Choi YS; Kim K; Kim J; Shim YM; Koh WJ
    Clin Infect Dis; 2008 Aug; 47(4):496-502. PubMed ID: 18611154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment outcomes and survival based on drug resistance patterns in multidrug-resistant tuberculosis.
    Kim DH; Kim HJ; Park SK; Kong SJ; Kim YS; Kim TH; Kim EK; Lee KM; Lee SS; Park JS; Koh WJ; Lee CH; Shim TS
    Am J Respir Crit Care Med; 2010 Jul; 182(1):113-9. PubMed ID: 20224066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High clustering rate and genotypic drug-susceptibility screening for the newly recommended anti-tuberculosis drugs among global extensively drug-resistant
    Trisakul K; Nonghanphithak D; Chaiyachat P; Kaewprasert O; Sakmongkoljit K; Reechaipichitkul W; Chaiprasert A; Blair D; Clark TG; Faksri K
    Emerg Microbes Infect; 2022 Dec; 11(1):1857-1866. PubMed ID: 35792049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Whole-genome sequencing of clinical isolates from tuberculosis patients in India: real-world data indicates a high proportion of pre-XDR cases.
    Bhanushali A; Atre S; Nair P; Thandaseery GA; Shah S; Kuruwa S; Zade A; Nikam C; Gomare M; Chatterjee A
    Microbiol Spectr; 2024 May; 12(5):e0277023. PubMed ID: 38597637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Study on the resistance of rifampicin-resistant Mycobacterium tuberculosis to anti-tuberculosis drugs in group A].
    Dai XW; Li CY; Wang NH; Chen SS; Tian LL; Zhao YF; Tao LY; Yang XY; Ding BC; He XX
    Zhonghua Jie He He Hu Xi Za Zhi; 2023 Nov; 46(11):1110-1117. PubMed ID: 37914422
    [No Abstract]   [Full Text] [Related]  

  • 18. Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB).
    Liu Y; Matsumoto M; Ishida H; Ohguro K; Yoshitake M; Gupta R; Geiter L; Hafkin J
    Tuberculosis (Edinb); 2018 Jul; 111():20-30. PubMed ID: 30029909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A four-drug standardized short regimen for highly resistant TB in South-West Nigeria.
    Fadeyi MO; Decroo T; Ortuño-Gutiérrez N; Ahmed B; Jinadu A; El-Tayeb O; Adebola W; Kehinde A; Lynen L; Gils T
    Int Health; 2024 Jan; 16(1):123-125. PubMed ID: 37026448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New and repurposed drugs to treat multidrug- and extensively drug-resistant tuberculosis.
    Silva DR; Dalcolmo M; Tiberi S; Arbex MA; Munoz-Torrico M; Duarte R; D'Ambrosio L; Visca D; Rendon A; Gaga M; Zumla A; Migliori GB
    J Bras Pneumol; 2018 Apr; 44(2):153-160. PubMed ID: 29791557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.